Key facts
- Mynvax’s last known valuation is $29.8M.
- It has raised $12.7M; the latest was Later Stage VC ($5.6M) in May 2024.
- Notable investors include Accel, LetsVenture Technologies, Accel India, Legacy Assets, 1Crowd — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Mynvax
- ·The full record, as it builds
Funding rounds
No funding rounds for Mynvax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mynvax
Developer of novel drugs designed to be used in vaccines for respiratory viruses. The company's drugs specialize in the treatment of flu and infectious disease for the healthcare industry, enabling medical professionals to improve their patient's recovery.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2017
- Employees
- 28
- Website
- mynvax.com/
- Ownership
- Privately Held (backing)
Mynvax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mynvax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mynvax in its N-PORT filings yet. We sweep new filings monthly.